Get the Stockscreener App
87.00
29.77%
19.96
After Hours:
87.38
0.38
+0.44%
Protagonist Therapeutics Inc stock is traded at $87.00, with a volume of 7.05M.
It is up +29.77% in the last 24 hours and up +50.68% over the past month.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
See More
Previous Close:
$67.04
Open:
$67.39
24h Volume:
7.05M
Relative Volume:
7.63
Market Cap:
$5.41B
Revenue:
$45.48M
Net Income/Loss:
$169.95M
P/E Ratio:
33.21
EPS:
2.62
Net Cash Flow:
$230.85M
1W Performance:
+34.20%
1M Performance:
+50.68%
6M Performance:
+112.77%
1Y Performance:
+99.59%
1-Day Range:
$65.75
$93.25
1-Week Range:
$62.24
$93.25
52-Week Range:
$33.31
$93.25
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
Name
Protagonist Therapeutics Inc
Sector
Industry
Phone
(510) 474-0170
Address
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Compare PTGX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PTGX
Protagonist Therapeutics Inc
|
87.00 | 4.17B | 45.48M | 169.95M | 230.85M | 2.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-17-25 | Initiated | Barclays | Overweight |
| Sep-12-25 | Initiated | Leerink Partners | Outperform |
| Jun-17-25 | Initiated | Citigroup | Buy |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Dec-06-24 | Initiated | Goldman | Neutral |
| Nov-05-24 | Initiated | Wedbush | Outperform |
| Sep-24-24 | Initiated | TD Cowen | Buy |
| Sep-09-24 | Initiated | Truist | Buy |
| Oct-30-23 | Initiated | CapitalOne | Overweight |
| May-25-23 | Resumed | Jefferies | Buy |
| Aug-25-22 | Initiated | JMP Securities | Mkt Outperform |
| Feb-11-22 | Initiated | BTIG Research | Buy |
| Oct-12-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-11-21 | Upgrade | Northland Capital | Market Perform → Outperform |
| Sep-20-21 | Downgrade | JP Morgan | Overweight → Neutral |
| May-24-21 | Initiated | JMP Securities | Mkt Outperform |
| May-24-21 | Initiated | Northland Capital | Outperform |
| Jan-06-21 | Initiated | JP Morgan | Overweight |
| Dec-16-20 | Initiated | Piper Sandler | Overweight |
| Sep-18-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-15-20 | Initiated | Jefferies | Buy |
| May-18-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-19 | Initiated | H.C. Wainwright | Buy |
| May-09-19 | Upgrade | Stifel | Hold → Buy |
| Dec-06-18 | Initiated | Nomura | Buy |
| Jan-29-18 | Initiated | Stifel | Buy |
| Jul-21-17 | Initiated | BTIG Research | Buy |
View All
Protagonist Therapeutics Inc Stock (PTGX) Latest News
Douglas Lane Adds $6 Million in J&J Stock Ahead of Earnings and Possible Biotech Deal - The Motley Fool
Protagonist Therapeutics (PTGX) Surges on Johnson & Johnson Acquisition Talks - GuruFocus
Key deals this week: Protagonist Therapeutics, Bristol Myers, Novo Nordisk, Fifth Third Bancorp and more - Seeking Alpha
Protagonist Therapeutics (NASDAQ:PTGX) Stock Price Up 9.4%What's Next? - MarketBeat
Protagonist Therapeutics: Small Biotech Skyrockets on Buyout Buzz & Breakthrough Trials - ts2.tech
Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) 51% Price Boost Is Out Of Tune With Revenues - simplywall.st
Protagonist Therapeutics (NASDAQ:PTGX) Sets New 12-Month HighHere's What Happened - MarketBeat
Protagonist Therapeutics Inc. (PTGX) Stock Price | Live Quotes & Charts | NSD - StocksToTrade
Pharma, Battery, And Biotech Stocks See Sudden Price Jumps - Finimize
Protagonist Therapeutics (PTGX) Surges on Takeover Speculation - GuruFocus
Why Protagonist Therapeutics Stock Skyrocketed by Almost 30% Today - Yahoo Finance
Protagonist Therapeutics Stock Notable Surge - timothysykes.com
Protagonist Therapeutics’s Recent Commendable Performance - StocksToTrade
Johnson & Johnson in talks to acquire Protagonist Therapeutics, source says - Reuters
Sudden Surge: PTGX’s Momentous Journey - timothysykes.com
Protagonist Therapeutics (PTGX) Skyrockets on J&J Buyout Buzz Amid Clinical Breakthroughs - ts2.tech
Protagonist Therapeutics stock reaches all-time high at 73.34 USD - Investing.com
Protagonist Therapeutics Sees Surging Stock Price: What’s Driving This? - StocksToTrade
Why Did Protagonist Therapeutics Stock Soar Today? - MSN
Johnson & Johnson In Talks To Acquire Protagonist Therapeutics: Report - Benzinga
Protagonist Therapeutics (PTGX) Stock Surges Over 34% - GuruFocus
Johnson & Johnson in Acquisition Talks with Protagonist TherapeuticsNews and Statistics - IndexBox
Stocks making the biggest moves midday: MP Materials, Alibaba, Protagonist Therapeutics & more - CNBC
Johnson & Johnson in Talks to Buy Protagonist Therapeutics: WSJ - Bloomberg.com
Protagonist Therapeutics (PTGX) Surges on Potential Johnson & Jo - GuruFocus
Protagonist Therapeutics surges after media reports J&J in talks to buy co - TradingView
J&J reportedly in talks to buy Protagonist (JNJ:NYSE) - Seeking Alpha
Johnson & Johnson in talks to acquire Protagonist Therapeutics, WSJ reports - Yahoo Finance
Protagonist Therapeutics stock surges after J&J acquisition talks report By Investing.com - Investing.com South Africa
Johnson & Johnson In Talks To Buy Protagonist TherapeuticsWSJ - TradingView
Exclusive | Johnson & Johnson in Talks to Buy Protagonist Therapeutics - The Wall Street Journal
Protagonist Therapeutics' (PTGX) "Sell (D+)" Rating Reaffirmed at Weiss Ratings - MarketBeat
What machine learning models say about Protagonist Therapeutics Inc.July 2025 Decliners & Weekly High Potential Stock Alerts - newser.com
Protagonist Stock Surges on Johnson & Johnson Report - The Wall Street Journal
Using data models to predict Protagonist Therapeutics Inc. stock movementPortfolio Risk Report & Weekly Watchlist of Top Performers - newser.com
Is Protagonist Therapeutics Inc. a candidate for recovery play2025 Top Decliners & Technical Confirmation Trade Alerts - newser.com
Predicting Protagonist Therapeutics Inc. trend using moving averages2025 Short Interest & Stepwise Entry/Exit Trade Alerts - newser.com
Protagonist Therapeutics (PTGX): Evaluating Valuation After Positive Phase 2b Trial Data and Pipeline Momentum - simplywall.st
Protagonist Announces Presentations of Clinical Data with Icotrokinra in Plaque Psoriasis and Preclinical Data with PN-881 at the EADV 2025 Congress - Livingston Daily
Protagonist Announces New Icotrokinra Data in Ulcerative Colitis Showing Potential for a Standout Combination of Therapeutic Benefit and a Favorable Safety Profile in Once-daily Pill - DelmarvaNow.com
Protagonist Therapeutics Inc Stock Analysis and ForecastMorning Star Patterns & Get Alerts on Stocks Set to Skyrocket - earlytimes.in
BMO Capital reiterates Outperform rating on Protagonist Therapeutics stock By Investing.com - Investing.com Canada
Protagonist Therapeutics, Inc. Experiences Revision in Stock Evaluation Amid Strong Market Performance - Markets Mojo
Wedbush Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $70 - 富途牛牛
Will Icotrokinra’s Phase 2b Success Shift Protagonist Therapeutics' (PTGX) Ulcerative Colitis Narrative? - simplywall.st
Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025 - USA Today
Protagonist Therapeutics' (PTGX) Buy Rating Reiterated at HC Wainwright - MarketBeat
HC Wainwright & Co. Reiterates Protagonist Therapeutics (PTGX) Buy Recommendation - Nasdaq
PTGX: HC Wainwright & Co. Reiterates Buy Rating with $80 Target Price | PTGX Stock News - GuruFocus
Protagonist Therapeutics stock price target raised to $74 at Clear Street - Investing.com
Protagonist Therapeutics (PTGX) Reports Promising Phase 2b Resul - GuruFocus
Protagonist Therapeutics Inc Stock (PTGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Protagonist Therapeutics Inc Stock (PTGX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Waddill William D. | Director |
Sep 22 '25 |
Sale |
64.25 |
4,000 |
257,000 |
5,130 |
5.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):